UBS Group
KYNB

UBS Group’s Kyntra Bio KYNB Stock Holding History

UBS Group’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,000
Closed -$88.6K – 9521
2023
Q4 		$88.6K Hold
4,000
– – ﹤0.01% 6238
2023
Q3 		$86.3K Buy
+4,000
New +$157K ﹤0.01% 5930

Other funds holding KYNB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

UBS Group's KYNB Position: Q1 2026 in Review

UBS Group increased its Kyntra Bio (KYNB) stake by 193% in Q1 2026, buying an estimated $142K and bringing the position to 27,591 shares worth $187K. The position accounts for ﹤0.01% of the portfolio, ranked #6676.

UBS Group first reported a position in KYNB in Q4 2014 and has held it in 46 quarters since. The position peaked at $7.9M in Q1 2018. 32 funds tracked by Wall St. Rank hold KYNB as of Q1 2026.

  • UBS Group held 27,591 shares of Kyntra Bio worth $187K as of Q1 2026.
  • UBS Group bought 18,159 Kyntra Bio shares in Q1 2026, an estimated $142K.
  • Kyntra Bio made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6676 holding.
  • UBS Group first reported a position in Kyntra Bio in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Kyntra Bio position peaked at $7.9M in Q1 2018.
  • 32 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.